The United States has emerged as a global leader in the diagnosis and treatment of Gaucher disease, supported by advanced healthcare infrastructure, widespread access to genetic testing, and strong investment in rare disease research. The presence of leading biopharmaceutical companies, favorable orphan drug policies, and continuous innovation in enzyme replacement and substrate reduction...